ODAC to review Amgen’s Nplate, ESAs
FDA's Oncologic Drugs Advisory Committee will meet March 12-13 to review the cumulative data, including recent study results, on the risk of erythropoeisis-stimulating agents in patients with cancer and to consider the BLA for Amgen's platelet producer Nplate (romiplostim). Discussion regarding the safety of ESAs will focus on Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit as well as Roche's Mircera, FDA says in the Jan. 25 Federal Register. At the last ODAC review of ESA safety, the panel recommended that sponsors conduct additional trials to support continued marketing in the oncology setting (1"The Pink Sheet" May 14, 2007, p. 3)...
You may also be interested in...
Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.
Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.